TrialThe lancet. Gastroenterology & hepatology2022

Perioperative nivolumab monotherapy versus nivolumab plus ipilimumab in resectable hepatocellular carcinoma: a randomised, open-label, phase 2 trial.

Ahmed Omar Kaseb et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.